Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations

By Walker D. K.   Davis J.   Houle C.   Gardner I. B.   Webster R.  

Xenobiotica, Vol. 39, Iss. 7, 2009-07 ,pp. : 534-543

Informa Healthcare

Access to resources Recommend Favorite

Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors

By Famiglini Valeria   Coluccia Antonio   Brancale Andrea   Pelliccia Sveva   La Regina Giuseppe   Silvestri Romano  

Future Medicinal Chemistry, Vol. 5, Iss. 18, 2013-12 ,pp. : 2141-2156

Future Science

Access to resources Recommend Favorite

Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man

By Allan G.   Davis J.   Dickins M.   Gardner I.   Jenkins T.   Jones H.   Webster R.   Westgate H.  

Xenobiotica, Vol. 38, Iss. 6, 2008-06 ,pp. : 620-640

Informa Healthcare

Access to resources Recommend Favorite

Structures of Tyr188Leu Mutant and Wild-type HIV-1 Reverse Transcriptase Complexed with the Non-nucleoside Inhibitor HBY 097: Inhibitor Flexibility is a Useful Design Feature for Reducing Drug Resistance

By Hsiou Y.   Das K.   Ding J.   Clark Jr A.D.   Kleim J-P.   Rösner M.   Winkler I.   Riess G.   Hughes S.H.   Arnold E.  

Journal of Molecular Biology, Vol. 284, Iss. 2, 1998-11 ,pp. : 313-323

Academic Press

Access to resources Recommend Favorite

Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in dog, cynomolgus monkey and mini-pig

By Ismail I. M.   Dear G. J.   Mutch P. J.   Davies L. H.   Plumb R. S.   Sweatman B. C.  

Xenobiotica, Vol. 29, Iss. 9, 1999-09 ,pp. : 957-967

Informa Healthcare

Access to resources Recommend Favorite